Cybin (HELP) Total Non-Current Liabilities (2021 - 2025)

Cybin's (HELP) quarterly Total Non-Current Liabilities came in at $28.9 million in Q3 2025, up 294.89% YoY from $7.3 million in Q3 2024, and down 35.08% on a QoQ basis from $44.5 million in Q2 2025.

Cybin (HELP) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends

Cybin (HELP) has 5 years of Total Non-Current Liabilities data on file, last reported at $28.9 million in Q3 2025.

  • Quarterly Total Non-Current Liabilities rose 294.89% year-over-year to $28.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.9 million (up 294.89% YoY) and the FY2024 annual result came in at -$11.5 million, changed N/A from the prior year.
  • Total Non-Current Liabilities retreated to $28.9 million in Q3 2025, from $44.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $44.5 million in Q2 2025 to a low of -$15.2 million in Q2 2024.
  • A 5-year average of $72554.6 and a median of -$4.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 33253.61% — and 2025, when it soared 392.28%.
  • Tracing HELP's Total Non-Current Liabilities over 5 years: stood at -$4.4 million in 2021, then dropped by 9.02% to -$4.8 million in 2022, then jumped by 100.64% to $30850.5 in 2023, then plunged by 33253.61% to -$10.2 million in 2024, then surged by 382.44% to $28.9 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $28.9 million (Q3 2025), $44.5 million (Q2 2025), and -$10.2 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Cybin 417.29 Mn 417.29 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 28.89 Mn
Jun 30, 2025 44.50 Mn
Dec 31, 2024 -10.23 Mn
Sep 30, 2024 -14.82 Mn
Jun 30, 2024 -15.23 Mn
Mar 31, 2024 -11.53 Mn
Dec 31, 2023 30,850.49
Sep 30, 2023 -3.78 Mn
Jun 30, 2023 173,457.42
Feb 28, 2023 226,867.54
Dec 31, 2022 -4.79 Mn
Sep 30, 2022 -4.90 Mn
Dec 31, 2021 -4.40 Mn
Sep 30, 2021 -4.47 Mn
Jun 30, 2021 626,415.91
Mar 31, 2021 864,368.44